Repair and extracellular-matrix peptides
BPC-157, GHK-Cu, thymosin beta-4, and TB-500 evidence separated by entity, route, and human relevance.
CONNECTED RECORDS
Repair and extracellular-matrix peptides: evidence by entity.
BPC-157
Interest in BPC-157 is driven by broad preclinical findings. The central evidence gap is not whether animal signals exist, but whether a defined product is safe and effective in people.
Open evidence recordGHK-Cu
GHK-Cu is biologically active and has limited topical human research, but the evidence does not validate broad injectable, systemic, or anti-aging claims.
Open evidence recordThymosin Beta-4
Thymosin beta-4 has early human development work and extensive preclinical biology, but that record does not establish routine systemic recovery use or equivalence to TB-500 products.
Open evidence recordTB-500
The first question for TB-500 is entity identity: evidence about full-length thymosin beta-4 should not be treated as direct evidence for every TB-500 product.
Open evidence record